Drug Profile
Research programme: Fc fusion protein vaccines - Tunitas Therapeutics
Alternative Names: GFD; Human Fcγ1-Fel d1 fusion proteinLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Tunitas Therapeutics
- Class Recombinant fusion proteins
- Mechanism of Action Fc gamma receptor IIB antagonists; IgE receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergy in USA (Parenteral)
- 13 Dec 2013 Preclinical development is ongoing